ConductScience.org, home

Paper42344690

Case Report: Alectinib and CNS-directed therapy for primary or relapsed ALK-positive anaplastic large cell lymphoma with central nervous system involvement.

Mikalonytė M and 16 others. Front Oncol, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Case Report: Alectinib and CNS-directed therapy for primary or relapsed ALK-positive anaplastic large cell lymphoma with central nervous system involvement. Papers, record 42344690. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42344690

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Case Report: Alectinib and CNS-directed therapy for primary or relapsed ALK-positive anaplastic large cell lymphoma with central nervous system involvement.
PubMed
Journal
Front Oncol
PubMed
Year
2026
PubMed
Publication types
Case Reports, Journal Article
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-08-13
PubMed

Authors17

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Mikalonytė MMilda
2Landsbergis VVilhelmas
3Kevličius LLukas
4Černauskienė SSkirmantė
5Davainis LLinas
6Žučenka AAndrius
7Trociukas IIgoris
8Pileckytė RRegina
9Davainienė BBirutė
10Šlepikienė IInga
11Ražanskienė GGintarė
12Mickys UUgnius
13Ražanskas JJonas
14Dementavičienė JJūratė
15Stoškus MMindaugas
16Batiuškaitė RRaminta
17Griškevičius LLaimonas

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References33

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
130687633ALK Inhibitors in the Treatment of ALK Positive NSCLC.Front Oncol2018https://conductscience.org/library/papers/30687633PubMed
240921094Anaplastic lymphoma kinase-positive primary CNS anaplastic large cell lymphoma in a pediatric patient: illustrative case.J Neurosurg Case Lessons2025https://conductscience.org/library/papers/40921094PubMed
330992232Treatment of Refractory ALK Rearranged Anaplastic Large Cell Lymphoma With Alectinib.Clin Lymphoma Myeloma Leuk2019https://conductscience.org/library/papers/30992232PubMed
428974506Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma.Blood2017https://conductscience.org/library/papers/28974506PubMed
538865667Brigatinib in ALK-Positive ALCL after Failure of Brentuximab Vedotin.N Engl J Med2024https://conductscience.org/library/papers/38865667PubMed
623109692Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial.J Clin Oncol2013https://conductscience.org/library/papers/23109692PubMed
717519389Pathobiology of ALK+ anaplastic large-cell lymphoma.Blood2007https://conductscience.org/library/papers/17519389PubMed
825153538
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
Lancet Oncol2014https://conductscience.org/library/papers/25153538PubMed
915800313Primary CNS lymphoma of T-cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group.J Clin Oncol2005https://conductscience.org/library/papers/15800313PubMed
1028459613Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients From the French Lymphopath Network.J Clin Oncol2017https://conductscience.org/library/papers/28459613PubMed
1126753004ALK inhibitors in non-small cell lung cancer: the latest evidence and developments.Ther Adv Med Oncol2016https://conductscience.org/library/papers/26753004PubMed
1226736010Abrupt Relapse of ALK-Positive Lymphoma after Discontinuation of Crizotinib.N Engl J Med2016https://conductscience.org/library/papers/26736010PubMed
1332420302Central nervous system relapse in a pediatric anaplastic large cell lymphoma patient with CLTC/ALK translocation treated with alectinib: A case report.World J Clin Cases2020https://conductscience.org/library/papers/32420302PubMed
1434132378Traditional and emerging therapies for anaplastic large cell lymphoma (Review).Int J Oncol2021https://conductscience.org/library/papers/34132378PubMed
1531226541Central nervous system relapse of systemic ALK-rearranged anaplastic large cell lymphoma treated with alectinib.Leuk Res2019https://conductscience.org/library/papers/31226541PubMed
1623061678Gemcitabine, oxaliplatin and dexamethasone as salvage treatment for elderly patients with refractory and relapsed peripheral T-cell lymphoma.Leuk Lymphoma2013https://conductscience.org/library/papers/23061678PubMed
1735373356Evaluation of Lorlatinib Cerebrospinal Fluid Concentrations in Relation to Target Concentrations for Anaplastic Lymphoma Kinase (ALK) Inhibition.J Clin Pharmacol2022https://conductscience.org/library/papers/35373356PubMed
1818385450
ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project.
Blood2008https://conductscience.org/library/papers/18385450PubMed
1940672809Involvement of the central nervous system in relapsed T-cell lymphoma: insights from four case studies.Leuk Res Rep2025https://conductscience.org/library/papers/40672809PubMed
209166827A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project.Blood1997https://conductscience.org/library/papers/9166827PubMed

See all 33 referencesDownload CSV of references

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
ALK238PubTator's text mininghttps://conductscience.org/library/genes/238

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42344690

GET https://conductscience.org/api/papers/v1/42344690/references?page=2